Genetic alterations in non-small cell lung cancer (NSCLC) have been identified in recent years \[[@b1-jptm-2016-03-09]-[@b4-jptm-2016-03-09]\]. Epidermal growth factor receptor (*EGFR*), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (*KRAS*), and anaplastic lymphoma kinase (*ALK*) are the most commonly mutated oncogenes that involve the pathogenesis of lung cancer as "genetic drivers." Advanced NSCLC has a dismal prognosis with a short median overall survival \[[@b5-jptm-2016-03-09]\], but several selective EGFR tyrosine kinase inhibitors (TKIs) and an ALK inhibitor show effectiveness as personalized target therapy in patients who harbor those specific genetic mutations \[[@b3-jptm-2016-03-09],[@b6-jptm-2016-03-09]\]. According to guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology, mutation analysis is recommended and recent studies have demonstrated the cost-effectiveness of genetic screening, especially in Asians, who have a higher prevalence of *EGFR* mutations \[[@b7-jptm-2016-03-09],[@b8-jptm-2016-03-09]\].

Chromosomal alterations, closely related to unique histologic phenotypes through protein expression, determine differentiation, patterns, and cell types. The identification of typical morphological features of certain mutations allows retrospective speculation on underlying genetic alterations. Although *EGFR*, *KRAS*, and *ALK* mutations have generally been considered mutually exclusive in NSCLCs \[[@b9-jptm-2016-03-09]\], some cases harbor double mutations in a single tumor \[[@b10-jptm-2016-03-09]-[@b13-jptm-2016-03-09]\]. Identifying driver oncogenes in double-mutated tumors through morphologic differences and comparing the responsiveness of targeted therapies can help explain the pathogenesis of lung cancer and predict resistance to targeted therapy. Hence, we explored histologic features and genetic drivers of tumors with concomitant mutations and discovered the dominant mutation in carcinogenesis for each.

MATERIALS AND METHODS
=====================

A retrospective review was performed of biopsied and/or surgically resected cases diagnosed as NSCLC and tested for *EGFR*, *KRAS*, and *ALK* mutations in the Department of Pathology and Translational Genomics at Samsung Medical Center, Seoul, Korea from 2006 to 2014. Of 6,637 NSCLC patients, 6,595 *EGFR*, 5,177 *KRAS*, and 4,869 *ALK* mutation tests were performed. Among them, 2,387 patients (36.2%) had *EGFR*, 398 (7.7%) had *KRAS*, and 281 (5.8%) had *ALK* mutations. Based on these tests, we selected 12 patients with concomitant mutations in the same tumor.

Clinical data, including gender, age, smoking history, and previous concurrent chemoradiation therapy history were extracted from electronic medical records. All hematoxylin and eosin stained slides of selected cases were reviewed by two pathologists (T.L. and B.L.). Histologic classification was made according to the IASLC/American Thoracic Society (ATS)/European Respiratory Society (ERS) International Multidisciplinary Classification of Lung Adenocarcinoma, and typical pathologic features were re-evaluated, including cell type, nuclear and cytoplasmic characteristics.

We used two methods to evaluate *EGFR* mutations in the 18th, 19th, 20th, and 21st exon: Sanger sequencing and real time polymerase chain reaction after peptide nucleic acid (PNA)--clamping using the PNA clamping EGFR Mutation Detection Kit (Panagene, Inc., Daejeon, Korea). *KRAS* mutations were evaluated with Sanger sequencing in the 12th and 13th exon. Extracted genomic DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue was used for *EGFR* and *KRAS* analyses. *ALK* mutation tests were performed using immunohistochemical (IHC) (1:40, NCL-ALK, clone 5A4, Novocastra, Newcastle upon Tyne, UK) and fluorescence *in situ* hybridization (FISH) analysis (LSI ALK dual color break-apart probe, Dako, Glostrup, Denmark) with FFPE tissue. Diffuse strong positivity in the cytoplasm was regarded as positive in ALK IHC. In the FISH analysis, 50 non-overlapping nuclei were counted and 15% of break-apart probes were used as a cutoff value for positivity. Diffuse strong positive ALK IHC results were interpreted as a surrogate marker of *ALK* rearrangement \[[@b14-jptm-2016-03-09]\].

RESULTS
=======

Clinical characteristics
------------------------

Clinical data and pathologic features of the 12 patients with concomitant mutations are summarized in [Table 1](#t1-jptm-2016-03-09){ref-type="table"}. The age at diagnosis of patients ranged from 48 to 78 years old (median, 62 years old) and 75% of patients were female. All three male patients had a history of smoking (15--57 pack-years) in contrast to none of female patients. Five surgically resectable patients underwent lobectomy and seven clinical stage IV patients had a needle aspiration or biopsy from the lung, bronchus, lymph node, or adrenal gland.

Patient No. 5 received EGFR TKI targeted therapy for bone metastasis at 15 months after lobectomy. Patient No. 6 refused treatment with chemo- or targeted therapy and patient No. 7 had a history of lobectomy at an outside hospital without any other treatment 9 years prior to the lymph node biopsy. Patient No. 10 received neoadjuvant concurrent chemoradiation therapy prior to surgery. Patient No. 12 previously underwent lobectomy and was treated with gefitinib for 1 month and crizotinib for 4 months in China. She had no *EGFR* or *KRAS* mutation at the time of diagnosis at China. Aside from this patient, all other patients had no history of prior targeted therapy before mutation testing.

Mutational and histologic characteristics
-----------------------------------------

All 12 patients were diagnosed with adenocarcinoma and had an *EGFR* mutation. *EGFR* mutations of three patients were only detected with the PNA clamping method, while nine were confirmed by Sanger sequencing. Five (41.7%) had the missense L858R mutation in exon 21, four (33.3%) had the missense G719X mutation in exon 18, and three (25%) had a deletion in exon 19. Patient No. 8 had the L858R and G719X mutations at the same time and patient No. 12 had a missense R803W mutation at exon 20 that was not identified before targeted therapy at the outside hospital. No patient had a T790M point mutation, which is associated with resistance. Six patients had additional *KRAS* mutations and the other six had an *ALK* mutation (referred to as '*EGFR*-*KRAS*' and '*EGFR*-*ALK*' hereafter). Three among the six patients who showed positivity at ALK IHC were confirmed with FISH analysis.

*EGFR*-*KRAS* and *EGFR*-*ALK* tumors showed distinct morphologic characteristics. Six *EGFR*-*KRAS* patients had papillary, acinar, solid, and micropapillary patterns ([Fig. 1](#f1-jptm-2016-03-09){ref-type="fig"}). Among them, five patients had typical hobnail cell features with apical snouts; the remaining patient (patient No. 2) underwent needle aspiration and did not show any typical cell features. One patient (patient No. 4) had a focal columnar cell component and intraand extracytoplasmic mucin, which are similar morphologic features of NSCLC with a *KRAS* mutation. The other five patients did not show any mucin. Two of the six patients had intranuclear inclusions.

In contrast, six *EGFR*-*ALK* patients showed solid, cribriform and micropapillary patterns. Three of six patients had signet ring cells and intracytoplasmic mucin with or without extracytoplasmic mucin production, which are typical features of *ALK*-positive NSCLC. The others did not show any typical cell features or mucins. One patient had intranuclear inclusions.

Treatment responses and follow-up status
----------------------------------------

Seven patients had surgical resection and two were alive without targeted therapy and any evidence of relapse or progression, including one patient who received neoadjuvant concurrent chemoradiation therapy. One patient who had surgery and decided not to receive targeted therapy due to old age and underlying diabetes mellitus died of disease after 53 months from surgery (patient No. 1).

EGFR TKI included gefitinib (250 mg, orally, every day) and erlotinib (150 mg, orally, every day) and the ALK inhibitor was crizotinib (250 mg, orally, every day or twice daily). Three among six *EGFR*-*KRAS* patients received targeted therapy with EGFR TKI. All three patients showed partial responses, but two also showed disease progression after 7 and 20 months. In the *EGFR*-*ALK* patients, two were treated with EGFR TKI, two with ALK inhibitor and one received both EGFR TKI and ALK inhibitor therapy. Most patients treated with ALK inhibitor or EGFR TKI showed partial response or stable disease, but patient No. 12 with EGFR TKI showed progressive disease.

DISCUSSION
==========

Concomitant genetic alteration of NSCLC is unusual because *EGFR*, *KRAS*, and *ALK* mutations are widely known as mutually exclusive. Most are associated with acquired mutation after targeted therapy and are related to drug resistance. In previous studies, two different hypotheses were proposed to explain dual mutation in NSCLC \[[@b12-jptm-2016-03-09]\]. Underlying intratumoral heterogeneity of *EGFR* mutations \[[@b15-jptm-2016-03-09]\], different tumor cells may have different oncogenic driver mutations. Some authors have also suggested coexistence of mutations in the same tumor cells using IHC expression and mutation-specific antibodies \[[@b12-jptm-2016-03-09],[@b16-jptm-2016-03-09]\].

EGFR, as a growth factor membrane-bound receptor tyrosine kinase, controls cell proliferation and survival. Approximately 36% of patients with NSCLC in East Asia have *EGFR* mutations and 90% of mutations are exon 21 L858R or exon 19 deletion \[[@b17-jptm-2016-03-09]\]. These mutations increase tyrosine kinase activity, resulting in hyperactivation of the RAS-RAF-MEK-ERK pathway, which regulates cell proliferation, and the phosphoinositide 3-kinase--AKT--mammalian target of rapamycin pathway, which is associated with cell survival. RAS proteins are central mediators in EGFR tyrosine kinase signaling and also associated with cell proliferation and differentiation. In particular, *KRAS* mutations are common in lung cancer but less common in East Asia than in Western countries \[[@b18-jptm-2016-03-09]\]. ALK is a receptor tyrosine kinase. *ALK* fusion with various N-terminal fusion partners stimulates kinase activity, and signaling of these mutations are involved in cell growth, proliferation and apoptosis. Among NSCLCs, 3%--7% harbor *ALK* fusion \[[@b3-jptm-2016-03-09],[@b4-jptm-2016-03-09]\] and the majority of these fusions are associated with the echinoderm microtubule-associated proteinlike 4 (*EML4*) gene. *EML4*-*ALK* fusions are associated with EGFR TKI resistance \[[@b19-jptm-2016-03-09]\].

Typical histologic features of lung cancer with *EGFR*, *KRAS*, and *ALK* mutations have been described \[[@b20-jptm-2016-03-09]-[@b24-jptm-2016-03-09]\]. All of these mutations are frequent in adenocarcinoma and *EGFR* mutations are more common in tumors with papillary, micropapillary, acinar, and lepidic patterns than in others. Hobnail cell type and intranuclear inclusion are typical nuclear features of *EGFR* mutation-harboring tumors. A solid pattern and mucinous type are more frequent in *KRAS* mutation tumors. Extracellular mucin production, cribriform patterns, and signet ring cell features are more common in *ALK* mutation tumors.

In this study, we analyzed six *EGFR*-*KRAS* (1.5%) and six *EGFR*-*ALK* patients (2.1%) among *KRAS* and *ALK* mutation-positive NSCLC patients. The majority of *EGFR*-*KRAS* tumors showed typical histologic features of *EGFR* mutation, except one case which had focal morphologic features similar to *KRAS* mutation. In a previous study, NSCLC harboring a *KRAS* mutation showed resistance to EGFR TKI and adjuvant chemotherapy \[[@b2-jptm-2016-03-09]\]. In our study, however, three patients showed partial response to gefitinib and erlotinib for 7--29 months. Intratumoral heterogeneity of the mutation may explain this discordance between coexistent *KRAS* mutation and response to EGFR TKI therapy. Patient No. 2 had short progression-free survival (PFS) and disease progressed rapidly, while the other two patients had 20--29 months of PFS. Based on the evidence of morphologic phenotypes and responsiveness to targeted therapy, we expected these two patients to have coexistent mutations in the same tumor cells, and hypothesized that the *EGFR* mutation was the dominant driver oncogene in lung cancer, even if the tumor cells harbored an additional *KRAS* mutation.

In *EGFR*-*ALK* patients, some previous studies have shown acquired *EGFR* mutations as a mechanism of resistance to ALK inhibitor therapy \[[@b25-jptm-2016-03-09],[@b26-jptm-2016-03-09]\]. In our case, patient No. 12 had no *EGFR* or *KRAS* mutation and was treated with crizotinib in an outside hospital. After 4 months of ALK-targeted therapy, she acquired an additional *EGFR* mutation and showed poor response to erlotinib, which is consistent with previous studies. In the other four patients, however, diverse responses were identified with no resistance to gefitinib or crizotinib. Conflicting results of responsiveness to EGFR TKI and ALK inhibitor in *EGFR*-*ALK* patients in NSCLC have been reported in a few limited studies \[[@b10-jptm-2016-03-09],[@b27-jptm-2016-03-09]\]. Recently, Yang *et al.* \[[@b16-jptm-2016-03-09]\] investigated relationships between receptor phosphorylation and response to targeted therapy, and suggested that relative phospho-EGFR and ALK levels can be used to predict response.

Although the G719X mutation accounts for about 7% of *EGFR* mutated NSCLC in East Asia \[[@b17-jptm-2016-03-09]\], three of five *EGFR*-*ALK* patients had the *EGFR* exon 18 G719X missense mutation in our study. In addition, three of five *EGFR*-*ALK* patients showed typical histologic features of ALK-expressing adenocarcinoma. From these findings, we suspect that the *ALK* mutation determines morphological phenotypes and acts as a driver oncogene, and the *EGFR* mutation may also play an important role in oncogenesis. Accordingly, based on evaluation of the signaling pathway, including phosphorylation of receptor kinase, the modification or combination of EGFR TKI and ALK inhibitor offer promising treatments.

The small number of cases limited our analysis. Baldi *et al.* \[[@b12-jptm-2016-03-09]\] revealed the possibility of more frequent concomitant mutations than expected and Won *et al.* \[[@b13-jptm-2016-03-09]\] reported an increased proportion of NSCLC harboring concomitant *EGFR* and *ALK* mutations from 4.4% to 15.4% using more sensitive methods such as targeted next-generation sequencing (NGS) and mutant-enriched NGS. Greater numbers of previously undisclosed concomitantly mutated tumors can be identified using more sensitive and advanced techniques. Some authors also suggest that tumor burden of each mutation affects responses to targeted therapy. There may be a limitation to evaluating mutations from biopsy specimens, but the majority of patients who need to receive targeted therapy might be clinically unresectable and may only be diagnosed with biopsy. Thus, the expectation of tumor burden in a limited biopsy specimen is unfavorable.

To the best of our knowledge, this is the first study to describe double mutated NSCLC with histologic findings. Morphologic findings might help predict underlying driver mutations and further studies are warranted.

In conclusion, we investigated genetic driver mutations in 12 double mutated NSCLCs with analysis of clinical and pathologic features. The majority of *EGFR*-*KRAS* tumors showed typical histologic patterns and cell features of *EGFR*-mutated tumors and partially responded to EGFR TKI. In *EGFR*-*ALK* tumors, however, some showed *ALK*-mutated features and partially responded to ALK inhibitor or EGFR TKI. EGFR and ALK play an important role in the oncogenesis of NSCLC and tumor morphology can provide important clues to predict treatment response. We suggest that patients with histologic features of *EGFR* mutations can be treated with EGFR TKI, even with coexistence of a *KRAS* mutation. We also suggest that *EGFR*-*ALK* patients should have underlying mutational pathways evaluated and be treated with a selection and/or combination of ALK inhibitor and EGFR TKI. Further studies are needed to support these interesting findings.
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![Histologic features of 12 pulmonary adenocarcinomas with concomitant mutations. (A--F) In the six *EGFR*-*KRAS* patients, patients No. 1 (A), No. 3 (C), No. 5 (E), and No. 6 (F) have papillary, micropapillary and acinar patterns with hobnail cells. (D) Patient No. 4 has an acinar pattern and hobnail cells for the most part but shows focal columnar cells with intra- and extracellular mucin. (B) Patient No. 2 does not show any typical cell features. (G--L) In the six *EGFR*-*ALK* patients, all patients show solid, cribriform or micropapillary patterns rather than the papillary or acinar patterns that are easily identified as *EGFR*-*KRAS* tumors. Patients No. 7 (G), No. 10 (J), and No. 11 (K) have signet ring cells with intra- or extracytoplasmic mucin. But in the other three patients, No. 8 (H), No. 9 (I), and No. 12 (L), typical cell features are not identified, as neither signet ring cells nor hobnail cells. *EGFR*, epidermal growth factor receptor; *KRAS*, v-Ki-ras2 Kirsten rat sarcoma viral oncogene; *ALK*, anaplastic lymphoma kinase.](jptm-2016-03-09f1){#f1-jptm-2016-03-09}

###### 

Clinicopathologic features of 12 patients with double mutated pulmonary adenocarcinoma

  Patient No.   Sex/Age(yr)   Smoking   Specimen    Stage    *EGFR* mutation                                              Additional mutation   Dominant pattern                                    Typical cell feature         Mucin                         Intranuclear inclusion   Surgery                                               Targeted therapy           Response    Status                                                 PFS (mo)
  ------------- ------------- --------- ----------- -------- ------------------------------------------------------------ --------------------- --------------------------------------------------- ---------------------------- ----------------------------- ------------------------ ----------------------------------------------------- -------------------------- ----------- ------------------------------------------------------ -----------------------------------------------------
  1             M/74          57PY      Lung/R      pT1bN1   E21 L858R                                                    *KRAS* I21S           Papillary and micropapillary                        Hobnail cells                No                            No                       \+                                                    \-                         \-          DOD^[a](#tfn1-jptm-2016-03-09){ref-type="table-fn"}^   \-
  2             F/62          Never     Lung/A      M1(IV)   E21 L858R                                                    *KRAS* G12D           ^[b](#tfn2-jptm-2016-03-09){ref-type="table-fn"}^   No                           No                            Present                                                                        Gefitinib                  PR → PD     DOD                                                    7
  3             F/63          Never     Lung/R      pT1bNO   E21 L858R                                                    *KRAS* G13A           Papillary and acinar                                Hobnail cells                No                            No                       \+                                                    \-                         \-          NED                                                    \-
  4             F/48          Never     Lung/R      pT1bN2   E19 deletion                                                 *KRAS* G12V           Acinar and solid                                    Hobnail and columnar cells   Intra- and extracytoplasmic   No                       \+                                                    Erlotinib                  PR → PD     DOD                                                    20
  5             M/55          20PY      Lung/R      pT2N2    E19 deletion                                                 *KRAS* G13C           Solid and acinar                                    Hobnail cells                No                            Present                  \+                                                    Gefitinib                  PR          AWD                                                    29
  6             F/78          Never     Lung/B      M1(IV)   E18 G719X                                                    *KRAS* G12D           Papillary and acinar                                Hobnail cells                No                            No                       \-                                                    (refused)                  \-          AWD^[a](#tfn1-jptm-2016-03-09){ref-type="table-fn"}^   \-
  7             F/62          Never     LN/B        M1(IV)   E21 L858R^[c](#tfn3-jptm-2016-03-09){ref-type="table-fn"}^   *ALK*                 Solid and cribriform                                Signet ring cells            Intracytoplasmic              No                       \+^[d](#tfn4-jptm-2016-03-09){ref-type="table-fn"}^   Gefitinib                  PR          AWD^[a](#tfn1-jptm-2016-03-09){ref-type="table-fn"}^   18^[e](#tfn5-jptm-2016-03-09){ref-type="table-fn"}^
  8             F/62          Never     Lung/B      M1(IV)   E21 L858R                                                    *ALK*                 Solid and cribriform                                No                           No                            No                       \-                                                    Gefitinib and Crizotinib   SD and PR   AWD                                                    24
  E18 G719X                                                                                                                                                                                                                                                                                                                                                                                                                                 
  9             M/56          15PY      Lung/B      M1(IV)   E18 G719X^[c](#tfn3-jptm-2016-03-09){ref-type="table-fn"}^   *ALK*                 Solid                                               No                           No                            No                                                                             Crizotinib                 SD          DOD                                                    4
  10            F/68          Never     Lung/R      ypT2N2   E18 G719X^[c](#tfn3-jptm-2016-03-09){ref-type="table-fn"}^   *ALK*                 Solid, micropapillary and cribriform                Signet ring cells            Intra- and extracytoplasmic   Present                  \+                                                    \-                         \-          NED                                                    \-
  11            F/58          Never     Lung/B      M1(IV)   E19 deletion                                                 *ALK*                 Solid                                               Signet ring cells            Intracytoplasmic              No                       \-                                                    Crizotinib                 \-          AWD^[a](#tfn1-jptm-2016-03-09){ref-type="table-fn"}^   ^[e](#tfn5-jptm-2016-03-09){ref-type="table-fn"}^
  12            F/66          Never     Adrenal/B   M1(IV)   E20 R803W                                                    *ALK*                 Solid                                               No                           No                            No                       \+^[d](#tfn4-jptm-2016-03-09){ref-type="table-fn"}^   Erlotinib                  PD          AWD^[a](#tfn1-jptm-2016-03-09){ref-type="table-fn"}^   0.7

EGFR, epidermal growth factor receptor; PFS, progression-free survival; M, male; PY, pack-year; R, resection; E, exon; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene; DOD, died of disease; F, female; A, aspiration; PR, partial response; PD, progressive disease; NED, no evidence of disease; AWD, alive with disease; B, biopsy; LN, lymph node; ALK, anaplastic lymphoma kinase; SD, stable disease.

Lost to follow-up;

Cannot identify dominant architectural patterns in an aspiration slide;

Mutation detected only in PNA clamping method;

Have a history of lobectomy at outside hospital, prior to biopsy of metastatic lesion;

Cannot evaluate due to lost to follow-up.
